BioCryst Pharmaceuticals, Inc. ("BCRX") designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases.

According to the Complaint, on January 21, 2018, the merger agreement and the voting and support agreements were executed by Idera Pharmaceuticals, Inc. ("IDRA") and BCRX. The transaction was announced by joint press release on the morning of January 22, 2018.

On February 27, 2018, Defendants filed a Form S-4 Registration Statement with the United States Securities and Exchange Commission in connection with the Proposed Merger. The Complaint alleges that the Registration Statement fails to provide material information regarding the Proposed Merger.

This case was voluntarily dismissed on July 20, 2018.